Los Angeles, California


SYMPOSIUM INFORMATION

>General Information
>Faculty
>Program/Schedule
>Accreditation/CME Surveys
>Registration
>Privacy Policy
 

Check us out on Twitter!

@LA_HeartFailure
 

Sponsored by:
PIH Health Good Samaritan Hospital
Los Angeles, CA

Endorsed by:

Affiliated With:
INTERNATIONAL ACADEMY OF CARDIOLOGY

Related Conferences:


26th Annual

Heart Failure 2022
An Update on Therapy
March 4 & 5, 2022

IMPORTANT CME CREDIT NOTICE

CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed. Surveys are accessible after signing in with the email address you submitted during registration.

Surveys will be accessible online the day of the symposium and for 3 weeks following. You must complete the process by March 28, 2022 in order to receive your certificate. Certificates will be available online until November 1, 2022 and are printable directly from the website.

ACCREDITATION

The AAFP Credit System and the Commission on Continuing Professional Development (COCPD) will be reviewing the symposium's agenda for determination of CME credit status.

COURSE OVERVIEW
The 26th Annual Heart Failure 2022: An Update on Therapy virtual symposium has been designed to provide a comprehensive update on the prevention, diagnosis and management of heart failure. The program includes lectures presented by the internationally renowned faculty. The extensive list of topics has been selected to provide a high level, contemporary and clinically relevant update with a goal of improving the care of patients with heart failure.

PROGRAM OBJECTIVES
At the conclusion of this activity, the participants should be able to:

  1. Provide an update on the new definition of heart failure (HF)
  2. Describe new guideline updates in the treatment of HF with reduced ejection fraction
  3. Provide information on new therapy for HF with preserved ejection fraction
  4. Provide recommendations for genetic testing in patients with cardiomyopathies
  5. Summarize new recommendations of initiation of drug therapy and incorporation of new therapeutic interventions for HF
  6. Describe effective strategies for optimization of drug therapy in patients with HF
  7. Describe characteristics of HF in Hispanics and African Americans
  8. Describe the management of HF in patients with congenital heart disease
  9. Provide information on the diagnosis pitfalls of amyloidosis
  10. Evaluate the benefit of myocardial viability assessment prior to surgical revascularization
  11. Describe the impact of percutaneous coronary interventions in patients with HF
  12. Describe new classification of cardiogenic shock and effect of hemodynamic evaluation
  13. Provide an update on device therapy in chronic HF
  14. Review of new studies on catheter ablation for atrial fibrillation in patients with HF
  15. Provide an update on percutaneous valve repair and replacement in patients with HF
  16. Discuss the characteristics and the management of methamphetamine cardiomyopathy
  17. Provide information on the new study to evaluate specific therapy for peripartum cardiomyopathy
  18. Describe a practical approach guideline directed management of hypertrophic cardiomyopathy
  19. Describe surgical approaches to hypertrophic cardiomyopathy

TARGET AUDIENCE
This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.

NEEDS ASSESSMENT
Recent data continues to show an important gap between published guideline recommendations and practice and demonstrates that life-saving drugs and devices are underutilized (JACC 2019:73:2384) and indicates the need for education and incorporation of recent guidelines by clinicians. Recently approved drugs for the management of heart failure provide a great opportunity for improved outcome and need to be incorporated into the care of patients with heart failure. Innovations in the diagnosis and management of various cardiomyopathies need to be embraced by clinicians for the benefit of the patients. The Heart Failure 2022 symposium has been designed to provide a comprehensive update on many of the new diagnostic and therapeutic modalities as well as information on new practice guidelines for the management of patients with HF.

FACULTY DISCLOSURE
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.